Travere Therapeutics

TVTX41

$15.04arrow_drop_up4.84%$0.69

TVTX41

$15.04

arrow_drop_up4.84%$0.69

Performance History

Key Stats
Open	$14.37
Prev. Close	$14.40
EPS	-4.98
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	14.05	14.75
52 Week Range	5.12	14.79

Ratios







EPS	-4.98

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Travere Therapeutics (TVTX)

Travere Therapeutics, Inc. (TVTX) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for patients suffering from rare diseases. The company's mission is to transform the lives of these patients by providing them with effective treatments that address the underlying cause of their conditions. Travere Therapeutics is committed to improving patient outcomes and delivering value to its shareholders.

As of the latest available data, Travere Therapeutics has a market capitalization of $X billion, indicating the company's size and value in the market. The stock price history of TVTX shows the fluctuations in its value over time, reflecting the market's sentiment towards the company. Investors can track the performance of Travere Therapeutics and make informed decisions about buying or selling the stock based on their analysis of the market dynamics and company's outlook.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Eric M. Dube Ph.D.
Headquarters: San Diego
Employees: 462
Exchange: NASDAQ

Keep an eye on Travere Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Travere Therapeutics's (TVTX) price per share?

The current price per share for Travere Therapeutics (TVTX) is $15.04. The stock has seen a price change of $0.7 recently, indicating a 4.84% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Travere Therapeutics (TVTX)?

For Travere Therapeutics (TVTX), the 52-week high is $15.06, which is 0.1% from the current price. The 52-week low is $5.12, the current price is 193.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Travere Therapeutics (TVTX) a growth stock?

Travere Therapeutics (TVTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Travere Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Travere Therapeutics (TVTX) stock price performance year to date (YTD)?

As of the latest data, Travere Therapeutics (TVTX) has a year-to-date price change of 57.37%. Over the past month, the stock has experienced a price change of 67.17%. Over the last three months, the change has been 111.9%. Over the past six months, the figure is 109.54%.

help

Is Travere Therapeutics (TVTX) a profitable company?

Travere Therapeutics (TVTX) has a net income of -$376.33M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 61.18% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -123.9% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $145.24M, although specific revenue growth data is currently not available. The gross profit is $88.86M. Operating income is noted at -$376.74M. Furthermore, the EBITDA is -$275.06M.

help

What is the market capitalization of Travere Therapeutics (TVTX)?

Travere Therapeutics (TVTX) has a market capitalization of $1.1B. The average daily trading volume is 2.8M, indicating the stock's liquidity and investor engagement.

News

TRAVERE THERAPEUTICS

INDUCEMENT EQUITY GRANTS

RESTRICTED STOCK UNITS

9/12/2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy